These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30315689)

  • 1. Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience.
    Goutzamanis S; Doyle J; Higgs P; Hellard M
    J Viral Hepat; 2019 Feb; 26(2):218-223. PubMed ID: 30315689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Price analyses on direct-acting antiviral drugs of hepatitis C].
    Duan CAX; Sui BY; Chen ZD; Zhao K
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct; 54(10):1161-1164. PubMed ID: 33115205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care in homeless shelters.
    Kim S; Powell J; Naugle J; Ricco M; Magee C; Masson C; Zevin B; Bush D; Khalili M
    J Viral Hepat; 2021 Oct; 28(10):1488-1490. PubMed ID: 34003525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability of Patient-Reported Outcome and Experience Measures for Hepatitis C Treatment Among People Who Use Drugs.
    Madden A; Hopwood M; Neale J; Treloar C
    Patient; 2019 Apr; 12(2):259-265. PubMed ID: 30270403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
    Madden A; Hopwood M; Neale J; Treloar C
    PLoS One; 2018; 13(11):e0207226. PubMed ID: 30500863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
    Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
    Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
    Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
    Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C in a new therapeutic era: Recontextualising the lived experience.
    Whiteley D; Whittaker A; Elliott L; Cunningham-Burley S
    J Clin Nurs; 2018 Jul; 27(13-14):2729-2739. PubMed ID: 28960567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective.
    Jonas MC; Loftus B; Horberg MA
    Infect Dis Clin North Am; 2018 Jun; 32(2):481-493. PubMed ID: 29778267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current management of hepatitis C].
    Lange CM
    Med Monatsschr Pharm; 2015 Sep; 38(9):337-44; quiz 345-6. PubMed ID: 26731851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of acute and chronic HCV infection in persons with HIV coinfection.
    Sulkowski MS
    J Hepatol; 2014 Nov; 61(1 Suppl):S108-19. PubMed ID: 25443339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does HIV Influence Hepatitis C Cure Rates Using Direct-Acting Antivirals?
    de Mendoza C
    AIDS Rev; 2016; 18(2):112-3. PubMed ID: 27232507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatitis C virus infection and hepatocarcinogenesis].
    Berta E; Egresi A; Bacsárdi A; Gáspár Z; Lengyel G; Hagymási K
    Orv Hetil; 2019 Jun; 160(22):846-853. PubMed ID: 31131608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?
    Muir AJ; Naggie S
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2166-72. PubMed ID: 26192145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Hepatitis C and Direct Acting Antivirals.
    Westerhoff M; Ahn J
    Surg Pathol Clin; 2018 Jun; 11(2):287-296. PubMed ID: 29751875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
    Sorbera MA; Friedman ML; Cope R
    J Pharm Pract; 2017 Jun; 30(3):359-365. PubMed ID: 26902648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic update in hepatitis C].
    Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.